Clinical Trial Update: Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating inhaled liposomal amphotericin B to prevent invasive aspergillosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• Liposomal amphotericin B (amphotericin B liposomal)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Aspergillosis | Phase 2, Phase 3 | Status: COMPLETED